je.st
news
Tag: blockade
Vietnam supplier blockade continues over pollution concerns
2017-08-09 12:56:00| Daily apparel & textile news and comment - from just-style.com
Apparel brands could begin facing delays in production if Vietnamese villagers at Uniqlo supplier Pacific Crystal Textiles continue to blockade the factory over alleged pollution concerns.
Tags: concerns
continues
vietnam
supplier
French wine growers threaten Tour de France blockade over Cono Sur Chilean wine partnership
2016-03-04 11:09:00| Daily beverage news and comment - from just-drinks.com
The organisers of the Tour de France have met with wine growers in the country who are unhappy at the race's sponsorship deal with Concha y Toro's Chilean wine brand, Cono Sur.
Winchburgh's 44-Day Blockade
2016-01-12 10:45:00| Railway Technology
The 742 million Edinburgh Glasgow Improvement Project (EGIP) will electrify the Edinburgh to Glasgow main line that carries around 20,000 passengers each day and is Britain's busiest inter-urban route.
Tags: blockade
Mercks BRIDION (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery
2015-12-17 23:52:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BRIDION (sugammadex) Injection 100 mg/mL (equivalent to 108.8 mg/mL sugammadex sodium) for the reversal of neuromuscular blockade (NMB) induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558Doris Li, 908-740-1903orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 read more
Tags: approval
adults
surgery
induced
Merck Statement on FDA Advisory Committee Meeting for BRIDION (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium
2015-11-06 20:13:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss BRIDION (sugammadex). BRIDION is the proposed trade name for Mercks investigational agent for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Doris Li, 908-740-1903orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: or
statement
agent
meeting